CytRx Corporation (NASDAQ:CYTR) presented results from its on-going Phase 1b/2 trial of aldoxorubicin in combination with ifosfamide/mesna in patients with advanced sarcomas at the European Society for Medical Oncology (ESMO) 2016 Congress being held in Copenhagen, Denmark.

Of the 36 evaluable patients receiving either 170mg/m2 or 250mg/m2 of aldoxorubicin plus ifosfamide and mesna, 13 of 36 (36%) achieved a partial response of the target lesion by RECIST 1.1 criteria, 22 of 36 (61%) had stable disease, and one patient had progressive disease. Median progression-free survival has not been reached, and dose-limiting toxicities were not observed in either cohort. No clinically significant cardiac toxicities were seen. The most common Grade 3 or 4 adverse events were neutropenia (71%), anemia (54%), thrombocytopenia (17%) and febrile neutropenia (14%). There were nine treatment-related serious adverse events, and no treatment-related deaths. The trial has been expanded to allow continued enrollment of additional sarcoma patients at the 250 mg/m2 dose of aldoxorubicin with ifosfamide and mesna.

“The results to date demonstrate that aldoxorubicin combined with ifosfamide provides significant clinical benefit for sarcoma patients,” said Sant Chawla, M.D., F.R.A.C.P., the trial’s principal investigator and Director of the Sarcoma Oncology Center in Santa Monica, California. “More than one-third of sarcoma patients achieved a partial response for the target lesion and 61% had prolonged stable disease. Importantly, six patients with unresectable tumors achieved greater than 50% tumor shrinkage allowing some of them to become eligible for surgery. Further, we did not see any signs of cardiotoxicity including in patients that received approximately 10 times the cumulative maximum dose of doxorubicin.”

The Phase 1b/2 clinical study is a single-center trial that has enrolled 40 patients to date with locally advanced, unresectable, and/or metastatic soft tissue sarcoma, intermediate-grade or high-grade chondrosarcoma or osteosarcoma.  In the dose escalation phase, patients received either 170mg/m2 or 250mg/m2 of aldoxorubicin in combination with up to a 14-day continuous infusion of ifosfamide (1g/m2/day) plus mesna over a 28-day cycle. Up to six cycles of ifosfamide/mesna with aldoxorubicin can be administered, and aldoxorubicin may be continued until tumor progression or unacceptable toxicity occurs. The expansion phase will enroll patients at the 250mg/m2 dose of aldoxorubicin and will allow for patients that had received prior chemotherapy to be included. The primary endpoint of the study is safety, and secondary endpoints include overall response rates and progression-free survival. (Original Source)

Shares of Cytrx closed last Friday at $0.54, down $0.03 or -4.66%. CYTR has a 1-year high of $3.66 and a 1-year low of $0.52. The stock’s 50-day moving average is $0.58 and its 200-day moving average is $1.80.

On the ratings front, Cytrx has been the subject of a number of recent research reports. In a report issued on July 29, Jefferies Co. analyst Chris Howerton reiterated a Hold rating on CYTR, with a price target of $0.75, which implies an upside of 39.0% from current levels. Separately, on July 12, FBR’s Christopher James reiterated a Buy rating on the stock and has a price target of $3.

According to, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Chris Howerton and Christopher James have a total average return of 8.7% and -10.9% respectively. Howerton has a success rate of 52.5% and is ranked #781 out of 4183 analysts, while James has a success rate of 38% and is ranked #4028.

CytRx Corp. operates as a biopharmaceutical research and development company specializing in oncology. It provides clinical development of aldoxorubicin oncology pipeline for the treatment of cancer.